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To the Editor:
We congratulate Schaff and col-
leagues1 on their recent study. We
wish, however, to emphasize some
points that we believe they should
have taken into consideration.
We could not figure out how to
correlate the preoperatively used drug
with the survival rate (see original
Table 21). To agree with the results,
one should standardize the last echo-
cardiographic data of the lost patients
with those of the living patients. We
think that preoperative echocardio-
graphic status of the patient could not
be correlated with the survival of the
6th postoperative year. We could not
clearly understand whether it was pos-
tulated that thewall thickness of 22mm
(see original Figure 41) did not have an
impact on survival or whether one
would bring the survival to an expected
level with the use of drugs? We thinkThe Journalthat the original Figure 2 is in contra-
diction with the original Figure 4.1
Ommen and associates2 previ-
ously stated that the pressure gradi-
ent does not have an impact on
(cardiac) survival because their mor-
tality was also 6% in the nonob-
structive group. Nevertheless, there
was limited information because of
the lack of postoperative echocar-
diographic data in the myectomy
group with respect to postoperative
pressure gradient, wall thickness,
and left ventricular diameters.
The standardization of the groups
after inclusion of the final echocardio-
graphic data of the lost patients would
yield the definitive results of this
study.
Mert Kestelli, MD
Ismail Yurekli, MD
Mehmet Bademci
Izmir Ataturk Education and
Research Hospital
Izmir, Turkey
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TREATMENT FOR INFECTIVE
ENDOCARDITIS: DOES IT
COME AT THE EXPENSE OF
WORSE NEUROLOGIC
OUTCOMES?
To the Editor:
With much interest we read the
recent article of Funakoshi and col-
leagues,1 suggesting superior long-
term outcomes for patients with
infective endocarditis after early sur-
gical treatment relative to a purported
conventional treatment strategy.of Thoracic and Cardiovascular SurgerAlthough the results seem in line
with general consensus, several meth-
odologic issues arise, affecting the
validity of the study’s conclusions.
First, we would like to comment on
the definition of the study groups. The
conventional treatment group includes
patientswho have been treatedwith an-
tibiotics only, as well as patients who
have been operated on at a later stage.
In our opinion, these patients should
not be combined into a single treatment
group. To illustrate this, the in-hospital
mortality is 5% for both the early and
late surgical groups. On the other
hand, the mortality of the conventional
treatment group seems higher (5% vs
13%; P¼ .08), possibly caused by un-
favorable results in the nonsurgical
group. It would have been more infor-
mative to have 3 groups for compari-
son: patients after early surgical
treatment, patients after late surgical
treatment, and patients who have
been treated with antibiotics only.
Correspondingly, it is problematic to
interpret the result of the propensity-
matched comparison, because it re-
mains unclear how many patients in
the conventional treatment group have
undergone surgical treatment. To as-
sess the role of early surgical treatment
in infective endocarditis adequately, it
would be more instructive to compare
the results of early surgical treatment
with those of late surgical treatment.
Second, the chosen period of
14 days after the initial diagnosis as
cutoff point for early versus late
surgery seems questionable. Several
studies show that the risk of embolic
events dramatically drops as early as
1 week of antibiotic treatment.2 Ac-
cordingly, the European guidelines3
on this specific subject advise that
early surgical treatment should be per-
formed within several days after the
diagnosis, instead of after 14 days,
whenever there is an indication for
early operation.
Another point of concern is the
postoperative neurologic outcome.
Among patients who had complicat-
ing stroke on admission, 30% hady c Volume 144, Number 6 1537
